Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
NCT05432466 · DiSCOVER Phase 3Recruiting
- Lead sponsor
- Acer Therapeutics Inc. (Industry)
- Enrollment
- 150 (estimated)
- Start date
- 7 Nov 2022
- Primary completion
- 1 Mar 2029 (estimated)
- Study completion
- 1 Apr 2029
- Last update posted
- 24 Aug 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- ACER-002 (celiprolol) 200 mg BID Drug
- Placebo BID Drug
Conditions and primary outcome
- Vascular Ehlers-Danlos Syndrome
Primary outcome
Time to first occurrence of a vEDS-related clinical event requiring medical attention: Fatal/nonfatal cardiac or arterial events [including dissection or rupture], uterine rupture, intestinal rupture, and/or unexplained sudden death (Over the double-blind period (estimated to be 40 months))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05432466.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05432466 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.